| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V79864 | Antiproliferative agent-25 | antiproliferation agent-25 (Compound 3s4) is a selective PRMT5 inhibitor (IC50= 0.11 μM). | |
|
V34821 | Antitumor agent-101 | 2848632-52-8 | Antitumor agent-101 is a selective covalent inhibitor of lysine methyltransferase G9a/GLP, with IC50s of 8.5 nM and 5.5 nM for G9a and GLP, respectively. |
|
V77240 | AS-99 TFA | AS-99 TFA is a first-in-class, potent and specific ASH1L histone methyltransferase inhibitor (IC50= 0.79 µM, Kd= 0.89 µM) with anti-leukemia activity. | |
|
V12013 | AZ-505 2TFA salt | 1035227-44-1 | AZ-505(AZ505) 2TFA, the ditrifluoroacetate salt ofAZ-505, is an SMYD2 (SET and MYND domain-containing protein 2)inhibitor with anticancer activity. |
|
V99818 | AZ-PRMT5i-1 | 2918814-96-5 | AZ-PRMT5i-1 (Compound 28) is a potent, oral MTAP-selective PRMT5 inhibitor. |
|
V0394 | BRD4770 | 1374601-40-7 | BRD4770 (BRD-4770) is a novel and selective inhibitor ofG9a (ahistone methyltransferase, also known as euchromatin histone methyltransferase 2 (EHMT2))with anticancer activity. |
|
V2926 | C-7280948 | 587850-67-7 | C-7280948 (C7280948) is a selective PRMT1 (protein arginine methyltransferase) inhibitor with anticancer activity. |
|
V0386 | CPI-360 | 1802175-06-9 | CPI-360 is a novel, highly potent, selective, and SAM-competitive inhibitor of enhancer of zeste homolog 2 (EZH2) with potential antitumor activity. |
|
V0389 | CPI-169 | 1450655-76-1 | CPI-169 (CPI169) is a novel, potent, and selective inhibitor of EZH2 (enhancer of zeste homolog 2) inhibitor with anticancer activity. |
|
V132520 | CS-VIP 8 | CS-VIP 8 is a selective allosteric WDR5 protein inhibitor (Ki = 0.008 μM). | |
|
V94223 | CSV0C018875 hydrochloride | 474084-56-5 | CSV0C018875 hydrochloride is a G9a (EHMT2) inhibitor that inhibits G9a activity. |
|
V114275 | DC-PRC2in-01 | 120430-77-5 | DC-PRC2in-01 is a potent inhibitor of EZH2-EED interaction with an IC50 of 4.21 μM and a Kd of 4.56 μM. |
|
V19289 | DCLX069 | 792946-69-1 | DCLX069 (DCLX-069) is a novel,SAM-competitive and selective PRMT1 (protein arginine methyltransferase 1) inhibitor (IC50 =17.9 µM) with anticancer effects. |
|
V133494 | Derlotuximab | 340013-96-9 | Derlotuximab is a chimeric scFv-Fc(huIgG1) antibody expressed in CHO cells that targets histone H1. |
|
V52145 | E67-2 | 1364914-62-4 | As an E67 analogue, E67-2 is a low-toxic, selective KIAA1718 Jumonji domain inhibitor (antagonist) with IC50 of 3.4 µM. |
|
V3760 | EBI-2511 | 2098546-05-3 | EBI-2511 is anovel and orally available benzofuran derived EZH2 inhibitors that was discovered through a scaffold hopping approach based on the clinical compound of EPZ-6438. |
|
V0393 | EI1 (KB145943; EI 1) | 1418308-27-6 | EI1(KB-145943; EI-1) is a potent and selective inhibitor of EZH2 (Enhancer of zeste homolog 2) with potential antitumor activity. |
|
V0390 | EPZ015666 (GSK3235025) | 1616391-65-1 | EPZ015666 (GSK-3235025), an analog ofEPZ-015866, is a potent, selective and orally bioavailable inhibitor of PRMT5 (protein arginine methyltransferase) with antineoplastic activity. |
|
V0401 | EPZ004777 | 1338466-77-5 | EPZ004777 (EPZ-004777) is a potent and selective inhibitor of DOT1 Like Histone Lysine Methyltransferase (DOT1L) inhibitor with antineoplastic activity. |
|
V0379 | EPZ005687 | 1396772-26-1 | EPZ005687 (EPZ-005687) is a novel, potent and selective inhibitor of EZH2 (a histone lysine N-methyltransferase) with anticancer activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
